Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Monday. The firm set a “hold” rating on the medical research company’s stock.

Several other equities research analysts have also issued reports on the stock. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a research note on Friday, January 3rd. HC Wainwright reissued a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a research note on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Cytosorbents currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.67.

Cytosorbents Stock Down 1.0 %

Shares of CTSO opened at $1.04 on Monday. The stock’s 50-day moving average price is $0.92 and its 200-day moving average price is $1.03. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $56.87 million, a price-to-earnings ratio of -2.89 and a beta of 0.57. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.59.

Institutional Trading of Cytosorbents

Large investors have recently added to or reduced their stakes in the stock. Sargent Investment Group LLC boosted its holdings in Cytosorbents by 13.4% during the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after acquiring an additional 192,747 shares during the period. Atomi Financial Group Inc. purchased a new position in Cytosorbents in the third quarter valued at $51,000. Finally, Geode Capital Management LLC grew its position in shares of Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares in the last quarter. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.